BionTech's big Cancer Deal: Billions for the Hope-Bearer BNT327 From Bristol Myers!
Reading Time: 2 minutes
BionTech, the German biotechnology company known worldwide for its pioneering work on mRNA-based vaccines during the Covid-19 pandemic, is intensively advancing its research and development, particularly in the field of oncology. The company is pursuing a broad pipeline aimed at developing innovative immunotherapies to combat cancer and infectious diseases. In oncology, these include mRNA-based cancer immunotherapies, cell therapies, and antibodies. The company has over 20 clinical studies in Phase 2 and 3 in the field of oncology underway or in...
Read this article now with a free account.
Your benefits:
- Every month, you can read 5 articles from the premium section for free.
- Monthly 2 trial issues of the Trader newspaper for free.
- Create a personal watchlist with an overview of news about your stock.
